Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 8%
Hold 58%
Sell 25%
Strong Sell 0%

Bulls say

Moderna's projected product sales are expected to grow from $1.73 billion in 2025 to $2.15 billion in 2026, indicating a robust revenue trajectory fueled by its expanding pipeline of mRNA development candidates across various therapeutic areas. The company has also improved its gross margins from a low of 30% in 2023 back to 50% in 2025, alongside enhancements in manufacturing efficiency that could support a further increase of 10% over the next three years. Additionally, a recent $1.5 billion debt deal strengthens Moderna's balance sheet, providing increased flexibility to navigate uncertainties and capitalize on future opportunities.

Bears say

Moderna's negative outlook is primarily driven by a significant decline in COVID vaccine sales, dropping from $18 billion in 2022 to an anticipated $6.7 billion in 2023, alongside reduced revenue guidance for 2025 due to waning vaccination rates and competitive pressures. The potential for future revenue generation is further constrained by limited success in expanding its vaccine pipeline beyond respiratory diseases and growing uncertainty regarding European sales, particularly with ongoing negotiations for tender agreements. Consequently, the firm's projected enterprise value has decreased from $22.12 billion to $21.53 billion, reflecting a cautious stance on its long-term growth potential in the evolving pharmaceutical landscape.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 8% recommend Buy, 58% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.